Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Patients with cystic fibrosis (CF) experience significant bone mineral density (BMD) loss at a younger age than those without the disease, with greater decline observed among individuals with ...

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Depression and fluoxetine negatively impact bone mineral density and implant osseointegration independently suggests a study ...

Lung transplant patients should undergo annual bone health screenings using dual-energy X-ray absorptiometry for the first ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Research indicates that vitamin D supplementation during pregnancy positively impacts children's bone health and lean mass, ...

Supplementation with cholecalciferol during pregnancy linked to increased bone mineral content, bone mineral density, lean mass in offspring ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Diabetes poses a significant risk to bone health, leading to decreased bone mineral density and increased fracture ...